Antispychotics linked to greater risk of death in youths:
second generation antipsychotic (SGA)
Abnormal Involuntary Movement Scale (AIMS)
"SGAs have been linked with higher risk of death, strokes, and transient ischemic attacks (TIAs) in elderly people with behavior problems due to dementia.
All antipsychotics have been associated with the risk of sudden cardiac death due to an arrhythmia (irregular heart beat). To minimize this risk, antipsychotic medications should be used in the smallest effective dose when the benefits outweigh the risks. Your doctor may order an EKG to monitor for irregular heartbeat."
"Tardive dyskinesia (TD) is a side effect that develops with prolonged use of antipsychotics."
"Abnormal Involuntary Movement Scale (AIMS) completed regularly by their healthcare provider to monitor for TD."
"Second generation antipsychotics (SGAs) increase the risk of diabetes, weight gain, high cholesterol, and high triglycerides. (See “Serious Side Effects” section for monitoring recommendations."
In three placebo-controlled trials (n = 938; mean age: 82.4 years; range: 56-99 years) of aripiprazole in
elderly patients with psychosis associated with Alzheimer's disease, patients treated with aripiprazole
were at increased risk of death compared to placebo. The rate of death in aripiprazole-treated patients
was 3.5 % compared to 1.7 % in the placebo group. Although the causes of deaths were varied, most
of the deaths appeared to be either cardiovascular (e.g. heart failure, sudden death) or infectious (e.g.
pneumonia) in nature (see section 4.."
"Antidepressants Cause 40,000 Deaths a Year - But They're Handed Out Like Candy", may 2011
"Sudden Death of Cardiac Origin and Psychotropic Drugs"
"aripiprazole exposures reported to the Danish Poison Information Centre (DPIC) from June 2007 to May 2015. Information concerning demographics, ingested dose and symptoms was extracted from the DPIC database and medical records. Information on death and admission to hospital was obtained from Danish national registers. We analysed 239 cases, 86 concerning single-drug exposures to aripiprazole, and 153 cases where aripiprazole had been taken with at least one other substance (mixed-drug). The median ingested aripiprazole dose was 105 mg (IQR: 50-1680 mg) in the single-drug exposure group and 120 mg (IQR: 60-225 mg) in the mixed-drug exposure group. The most commonly reported symptom was light sedation, reported in 63% of the single-drug group and 50% of the mixed-drug exposure group. There were no malignant arrhythmias or ECG abnormalities after single-drug exposures. No deaths were recorded in relation to the intake. We found a long-term mortality rate of 13 deaths per 1000 person-years (95% CI: 7; 23 per 1000 person-years), which is significantly higher than in an age- and gender-matched background population"
"Abilify lawsuits claim the manufacturer failed to warn patients of serious side effects like compulsive behavior (gambling), stroke, hyperglycemia and type 2 diabetes. More than 2,500 Abilify lawsuits have been filed, some settling for a combined total of $534 million."
"2007 Abilify Settlement: $515 million
In September 2007, Bristol-Myers Squibb paid more than $515 million to settle a federal investigation into its marketing techniques for Abilify. The U.S. government claimed that between 2000 and 2003 pharmaceutical company made illegal payments to physicians for prescribing Abilify and provided similar illegal benefits to pharmacies that filled the prescriptions.
Furthermore, the government accused BMS of marketing their drug for off-label uses and to unapproved age groups. The allegations also claimed that the drugmaker had purposefully and irresponsibly inflated the price of the drug.
The settlement let BMS escape a full trial, but it also came with strings attached. Part of the agreement required the corporation to report accurate drug prices to the Office of Inspector General of the Department of Health and Human Services."